From bench to bedside a comprehensive review of pancreatic cancer immunotherapy

Kunk, Paul R.; Bauer, Todd W.; Slingluff, Craig L.; Rahma, Osama E.

doi:10.1186/s40425-016-0119-z

Table 3 On-going immunotherapy clinical trials

From: From bench to bedside a comprehensive review of pancreatic cancer immunotherapy

Treatment type	Phase	Target	N	Additional therapy	Stage	Identifier
Chimeric antibody	I,II	Ensituximab	116	None	Metastatic	NCT01040000^a
DNA vaccine	I	VEGFR-2	72	None	Metastatic	NCT01486329^a
Fungal vector vaccine	II	RAS	176	Gemcitabine	Resected	NCT00300950^a
Viral vector vaccine	I	Small Pox Virus	36	None	Metastatic	NCT00574977^a
Allogeneic vaccine	I	CEA	48	GM-CSF	Metastatic	NCT00028496^a
	I	Donor Lymphocyte	37	None	Metastatic	NCT00161187^a
	I	Dendritic cells	12	Poly-ICLC	Unresectable	NCT01677962
	II	GM-CSF	60	Cetuximab + Cyclophosphamide	Metastatic	NCT00305760^a
	II	GVAX	56	None	Metastatic	NCT00389610
	II	GVAX	87	Cyclophosphamide	Resectable	NCT0072744
	II	GVAX	19	Cyclophosphamide, Radiation, FOLFIRINOX	Resected	NCT01595321
	II	GVAX +/- Mesothelin	93	Cyclophosphamide	Metastatic	NCT01417000
	II	GVAX +/- Mesothelin	240	Gemcitabine, Capecitabine, 5-FU, Irinotecan, Erlotinib or Cyclophosphamide	Metastatic	NCT02004262
	II	IFN-α + GM-CSF	14	Cyclophosphamide	Metastatic	NCT00002773^a
	III	Virulizin	400	Gemcitabine +/- 5-FU	Metastatic	NCT00040092^a
Autologous vaccine	I	CEA	24	None	Metastatic	NCT00004604^a
	I	CEA	14	None	Metastatic	NCT00027534^a
	I	CEA	24	Denileukin Diftitox	Metastatic	NCT00128622^a
	II	CEA	48	IL-2	Metastatic	NCT01723306
	I	Dendritic Cells	2	Gemcitabine + Stereotactic Radiosurgery	Metastatic	NCT00547144^a
	II	KLH	35	Radiation	Metastatic	NCT00868114
Immunotherapy	I	B7-H3	93	none	All	NCT01391143
	I	CD40	10	Gemcitabine + nab-paclitaxel	Metastatic	NCT02588443
	I	CD40	10	Gemcitabine	resected	NCT01456585^a
	II	CTLA-4	82	None	Metastatic	NCT00112580^a
	I	CTLA-4	37	Gemcitabine	Metastatic	NCT00556023^a
	I	CTLA-4	28	Gemcitabine	Metastatic	NCT01473940
	II	CTLA-4 + GVAX	92	FOLFIRINOX	Metastatic	NCT01896869
	II	IDO	98	Gemcitabine + nab-paclitaxel	metastatic	NCT02077881
	I	IL-1-Ra	13	FOLFIRINOX	Metastatic	NCT02021422
	I/II	PD-1	56	Capecitabine + Radiation	Resectable and Borderline Resectable	NCT02305186
	I	PD-L1	1038	none	All	NCT01693562
Peptide vaccine	I,II	Alpha (1, 3) galactosyltransferase	7	None	Metastatic	NCT00255827^a
	III	Alpha (1, 3) galactosyltransferase	280	FOLFIRINOX	Locally Advanced	NCT01836432
	III	Alpha (1,3) galactosyltransferase	722	Gemcitabine, 5-FU, radiation	Resected	NCT01072981
	I,II	CEA	28	None	Metastatic	NCT00529984^a
	I	CEA + MUC1	18	None	Unresectable	NCT00669734
	I	hCG-β	36	None	Metastatic	NCT00648102^a
	I	hCG-β	48	None	Metastatic	NCT00709462^a
	I	Heat Shock Protein	16	None	Resected	NCT00003025^a
	I/II	Hedgehog	122	Gemcitabine	Metastatic	NCT01130142^a
	I	Hedgehog	21	FOLFIRINOX	Unresectable	NCT01383538
	I	MUC1	25	None	Resected or Locally Advanced	NCT00008099^a
	I/II	MUC5AC	90	Gemcitabine + nab-paclitaxel	Unresectable	NCT01834235
	I	P53	12	None	Unresectable	NCT01191684^a
	II	P53 + RAS	70	IL-2	Metastatic	NCT00019084^a
	I	RAS	7	None	Metastatic	NCT00006387^a
	I	RAS	33	None	Metastatic	NCT00019006^a
	III	Telomerase	1110	Capecitabine + Gemcitabine	Metastatic	NCT00425360^a
	I	TGF-β	168	Gemcitabine	Resectable and unresectable	NCT01373164
	I	Trophoblast glycoprotein	44	None	Metastatic	NCT00056537^a
	I/II	VEGF	17	Gemcitabine	Unresectable	NCT00655785^a
	I	VEGFR-2	21	Gemcitabine	Metastatic	NCT00622622^a

5-FU 5-flurouracil, CEA Carcinoembryonic antigen, CTLA-4 Cytotoxic T-lymphocyte associated protein-4, FOLFIRINOX folinic acid, fluorouracil, irinotecan, oxaliplatin, GM-CSF granulocyte macrophage colony stimulating factor, hCG Human chorionic gonadotropin, IDO indoleamine 2,3-dioxygenase, IFN interferon, IL-2 interleukin-2, KLH keyhole limpet hemocyanin, MUC mucin, N number, PD programmed death, PD-L programmed death ligand, Poly-ICLC carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA, TGF Transforming growth factor, VEGF Vascular endothelial growth factor, VEGF-R Vascular endothelial growth factor receptor
^aStudy listed as complete but results not published

Back to article page